Laboratory of Cell and Gene Therapy, Hyogo College of Medicine, Nishinomiya, Japan;
Department of Thoracic Surgery, Shinkomonji Hospital, Kitakyushu, Japan.
Anticancer Res. 2021 Feb;41(2):905-910. doi: 10.21873/anticanres.14843.
BACKGROUND/AIM: CD133 is a promising candidate marker for cancer stem cells. However, clinical studies on CD133 expression in human lung adenocarcinoma have not yet been conducted. We hypothesized that CD133 expression in lung adenocarcinoma is a poor prognostic factor.
CD133 expression in lung adenocarcinoma was examined clinicopathologically. Then, clinicopathological parameters and patient prognosis were investigated. Moreover, CD133 expression was examined via immunohistochemical staining, and the relationship between CD133 expression and clinicopathological parameters was explored.
Approximately 48.0% (49/102) of patients had CD133-positive cells. Based on a subgroup analysis, the CD133-positive group with pStage I+II disease had a significantly worse disease-free interval than the CD133-negative group (p<0.05).
CD133 expression may be a poor prognostic factor in lung adenocarcinoma.
背景/目的：CD133 是一种有前途的癌症干细胞候选标志物。然而，尚未对人类肺腺癌中 CD133 的表达进行临床研究。我们假设肺腺癌中 CD133 的表达是预后不良的因素。
通过临床病理检查来检测肺腺癌中 CD133 的表达。然后，对临床病理参数和患者预后进行了研究。此外，通过免疫组织化学染色检测了 CD133 的表达，并探讨了 CD133 表达与临床病理参数之间的关系。
约 48.0%（49/102）的患者存在 CD133 阳性细胞。根据亚组分析，pStage I+II 疾病的 CD133 阳性组与 CD133 阴性组相比，无病间隔明显更差（p<0.05）。
CD133 表达可能是肺腺癌的预后不良因素。
